September 30, 2019
Catabasis Pharmaceuticals’ third phase trial of edasalonexent in Duchenne muscular dystrophy exceeds target enrollment
Catabasis Pharmaceuticals has enrolled more than expected patients for its third phase PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD), for which it expects the top-line results in the fourth quarter of 2020.